№

Name of the project

№ agreement/contract

Client

Country-consumer of the development/service

1

Horizon 2020 "NanoSurf: Nanostructural surface development for dental implant manufacturing"

777926

EUROPEAN COMMISSION Research Executive Agency 

Ukraine, EU

2

Study on the efficiency of sewage treatment on sewage disposal facilities (Vyrivka, Konotop district, Sumy region); Conducting of hydrobiological research of parameters of sewage in bioponds of treatment facilities.

51.16-2020.СП/25  

Swiss Center for Resources and Development Consulting (Skat Consulting Ltd.)

Switzerland

Ukraine

3

PDD support for an information center to provide information about NATO and related topics to scholars, students and other stakeholders

RG 333 PR28175

NATO Information and Documentation Center

Belgium

4

Entrepreneurial risks of small and medium enterprises in Ukraine

GA_19/2020

Grants agency Academia Aurea

Czech Republic

5

PDD support information center to provide information about NATO and related topics to scholars, students and other interested members of the public

RG 494

NATO -Public Diplomacy Division

Belgium

6

Institutional development of the Center for Social and Humanitarian Aspects of Regional Studies of Sumy State University

SG53702

“Renaissance” International Foundation

Embassy of Sweden in Ukraine

7

Development of drawings of the test installation for modification of granules of nitrogen fertilizers and rendering of engineering services

1403-01

“Expofert OU” company

Estonia

8

Support for the recognition of qualifications for Ukrainian universities

609995-EPP-1-2019-1-PL-EPPKA2-CBHE-SP

Jagiellonian University

Krakow (Poland)

9

Scientific services for obtaining and conducting laboratory analytical studies of polymeric, composite materials, paints and varnishes, modified nano-materials according to application letters

51.19-2020/01

AG CHEMI GROUP s.r.o.

Czech Republic

10

Randomized, double-blind, placebo-controlled study of Cvac (autologous dendritic cells activated by recombinant human hybrid protein in combination with oxidized polymanose) when used as maintenance therapy of patient

01

SPRAY Clinical Trials LLC

Germany

11

A randomized, double-blind, phase II study to find the optimal dose to evaluate the safety and efficacy of veliparib and whole-brain radiation therapy compared to placebo in combination with whole-brain radiation therapy

АВТ-888, М10-897

Abbott Laboratories representative office

Switzerland

12

Carrying out of clinical researches in frame of  GM-IMAB-001-03

51/101-R12

PISI-Ukraine LLC

Germany

13

A randomized, double-blind, phase 3 study to evaluate the efficacy and safety of ABP 215 compared with bevacizumab in patients with advanced non-small cell lung cancer

20120265

Pharm Research Associates Russia

USA

14

A randomized, double-blind, phase 3 study to evaluate the combination of PF-06439535 with Paclitaxel-Carboplatin and the combination of Bevacizumab with Paclitaxel-Carboplatin in first-line treatment in patients with advanced non-squamous non-small cell

В7391003

Icon Clinical Research Ltd.

USA

15

A randomized, multicenter, double-blind study comparing the efficacy and safety of MYL 1401H and European-derived Neulasta® in patients with stage II / III breast cancer receiving neoadjuvant or adjuvant

WCT/MYL-1401H-3001/3809/IS

Foreign Enterprise Worldwide Clinical Trails-Ukraine

Milan GmbH

16

Open randomized multicenter with a single injection of the drug with two consecutive applications of drugs in two periods cross-comparative study of the bioequivalence of the drug IG-001 260 mg / m2

874/812
STI -102

MB QUEST LLC

USA

17

Overall survival of pembrolizumab (MK-3475) compared with standard treatment in naive (previously untreated) patients with PD-L1 positive advanced or metastatic non-small cell lung cancer (Kinout 042)

МК-3475-042-0289

MSD Ukraine LLC

Netherlands

18

A randomized, double-blind, phase III study comparing pembrolizumab treatment (MK-3475) in combination with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355)

МК-3475-355-1555

MSD Ukraine LLC

USA

19

A multinational, multicenter, randomized, open-label phase III study of pembrolizumab versus docetaxel in previously treated non-small cell lung cancer patients

МК-3475-033-0800

MSD Ukraine LLC

USA

20

A randomized, open-label phase III study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as first-line treatment in patients with locally progressive or metastatic clear cell carcinoma of the kidney

МК-3475-426-2800

MSD Ukraine LLC

USA

21

Production of plugs on own developed technology according to drawings of the buyer

12/17

CJSC "Western Project"

Republic of Belarus, Minsk

22

International multicenter randomized open-label study in parallel groups to evaluate the efficacy and safety of Docecal versus Taxotere

7   (OAS-12-DOC-BIO)

LLC "OST Ukraine"

Sweden

23

Study of phase 2 sodium cridanimod when used concomitantly with progestin therapy in patients with recurrent or persistent progesterone-negative endometrial cancer

VX-EC-2-2013

LLC "OST Ukraine"

USA

24

Clinical trials sponsored by Bavituximab

499681001-821і/2014

InnoPharm-Ukraine Contract Research Organization LLC

USA

25

Clinical trials of СТ-P6 sponsor product (transtuzumab)

486201001-3408і/2014

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

26

Phase 3 open-label randomized trial to evaluate the efficacy and safety of Atezolizumab

565531001-283965і/2015

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

27

An open, randomized phase 3 study of MPDL3280A (ANTI-PD - L1 antibody), in combination with the Carboplatin + Paclitaxel regimen, with or without Bevacizumab, compared to the Carboplatin + Paclitaxel + bevacizumab

564611001-280998i/2015    GO29436

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

28

Open, multicenter randomized phase 3 study to evaluate the efficacy and safety of MPDL3280A (ANTI-PD - L1 antibody), in combination with Carboplatin + Paclitaxel or MPDL3280A in combination with Carboplatin + Nab-paclitaxel

564611001-280760і/2015    GO29437

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

29

An open, randomized phase 3 study of Atezolizumab (MPDL3280A (ANTI-PD - L1 antibody)) in combination with the Carboplatin + Pemetrexed regimen in patients with non-squamous non-small cell lung cancer stage IV.

565521002-291840і/2016    GO29438

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

30

A multicenter, double-blind, randomized, parallel-group study to evaluate the efficacy and safety of MYL 1422O compared with Avastin as first-line therapy for the treatment of patients with non-squamous cell lung cancer IV

568151001-335і/2016

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

31

Open randomized phase 3 study of atezolizumab (MPSL3280A, antibody to PD-L1) in combination with carboplatin or cisplatin + pemetrexed compared to carboplatin or cisplatin + pemetrexed in patients with non-squamous cell carcinoma.

565521002-291840і/2016

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

32

Open-label randomized phase 3 study of atezolizumab versus platinum-based treatment regimen (cystaplatin or carboplatin) in combination with pemetrexed or gemcitabine for stage IV non-squamous or squamous cell lung cancer

564561001-305447і/2017
GO 29431

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

33

A randomized, double-blind, multi-center phase III study conducted in parallel groups to compare the efficacy and tolerability of Fulvestrant (FAZLODEXTM) 500 mg and Anastrozole (ARIMIDEXTM) 1 mg as a hormonal

D699ВС00001

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Sweden

34

Safety and efficacy of LONQUEX® (lipegfilgrastim) compared to pegfilgrastim (Neulasta®, Amgen Inc.] and placebo in patients with non-small cell lung cancer receiving first-line chemotherapy

ХМ22-ONC-40041_58201

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

35

"LUMINIST: a non-interventional study of the molecular mechanisms of lung cancer"

D1532R00004_Sumy-Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Sweden

36

A multicenter, randomized, double-blind phase III study to evaluate the efficacy and safety of VI 695502 in combination with chemotherapy compared to Avastin in combination with chemotherapy

1302.5_5418_Inst
WWA16924

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

37

An open-label, multicenter, single-group, international phase IIIb study to evaluate the safety and efficacy of VI 695502 plus mFOLFOX6 in previously untreated patients with locally advanced or metastatic colorectal cancer

1302.3_6010_Inst
WWA16924

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

38

Phase 3, double-blind, randomized trial to evaluate the efficacy and safety of AZD9291 compared with standard therapy with epidermal growth factor receptor tyrosine kinase inhibitors as a first-line treatment for patients with locally advanced

218344 D5160C00007 (AZD9291)

PAREXEL Ukraine LLC

Sweden

39

A randomized, phase 3 study of combination therapy with ganetespib and docetaxel versus docetaxel monotherapy in patients with advanced non-small cell lung adenocarcinoma

17/20-R13(9090-14)

PAREXEL Ukraine LLC

USA

40

A multicenter, randomized, double-blind, phase III study of the efficacy and safety of nintedanib oral docetaxel versus placebo-treated docetaxel in patients with stage IIIB / IV

1199.128
(70009/EIU)

PAREXEL Ukraine LLC

Germany

41

A randomized, double-blind, multicenter, phase 3 study comparing the efficacy, safety, pharmacogenetics, and immunogenicity of SB8 and Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer.

226810 SB8-G31-NSCLC

PAREXEL Ukraine LLC

Korea

42

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of AZD9291 versus placebo in patients with stage III-IIIA non-small cell lung cancer and receptor mutation.

220767/7706/EIH

PAREXEL Ukraine LLC

Belgium

43

A randomized, double-blind, parallel-group study comparing the efficacy and safety of FKB238-002 and Avastin when used as first-line therapy in combination with paclitaxel and carboplatin in patients with

7710/EIH(FKB238-002)

PAREXEL Ukraine LLC

USA

44

A randomized phase III study comparing abemacyclib therapy in combination with optimal symptomatic therapy and erlotinib in combination with optimal symptomatic therapy in patients with stage IV non-small cell lung cancer

JPBK/464

Eli Lily East SA Company

Switzerland

45

Phase II study of LY2606368 in the treatment of patients with advanced small cell lung cancer.

JTJH/253

Eli Lily East SA Company

Switzerland

46

A randomized phase II study comparing alternative doses of ramucirumab in combination with paclitaxel as second-line therapy in patients with metastatic or locally advanced inoperable gastric or gastroesophageal adenocarcinoma

JVCZ/360

Eli Lily East SA Company

Switzerland

47

Randomized, open-label, multicenter, international phase III study of MEDI4736 in combination with Tremelimumab compared with standard treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

D4193C00002
AZU4 1932-419302

Pharmaceutical Research Associates Ukraine LLC

Sweden

48

Study of intravenous vinflunine in combination with methotrexate compared with methotrexate monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who had previously received platinum chemotherapy

L00070 IN 309 F0

Pharmaceutical Research Associates Ukraine LLC

France

49

International, multicenter, randomized, open-label phase 3 study of MEDI4736 alone or in combination with Tremelimumab compared with standard chemotherapy for first-line treatment of patients with recurrent or metastatic squamous cell carcinoma.

Н-СТ 16/13 
D419LC00001

Astrazeneka Ukraine LLC

Sweden

50

A randomized, phase III, double-blind, placebo-controlled study to evaluate the efficacy and safety of Selumetinib (AZD6244; ARRY-142886) (Hydrosulphate) in combination with Docetaxel in patients receiving second-line treatment with

б/н від 17.02.2014
(D1532C00079)

Astrazeneka Ukraine LLC

Sweden

51

International, multicenter, randomized, open-label phase 3 study of MEDI4736 alone or in combination with Tremelimumab compared with standard chemotherapy for first-line patients with advanced or metastatic non-small cell lung cancer

Н-СТ 15/111

Astrazeneka Ukraine LLC

Sweden

52

An open label, multigroup phase 2 study to determine the preliminary efficacy of a new combination of treatment for patients with advanced small cell lung cancer refractory to platinum

М(Н)-СТ16/24,
D419QC00002

Astrazeneka Ukraine LLC

Sweden

53

An open, multicenter phase 2 study to determine the preliminary efficacy of a new combination of treatments for patients with advanced small cell lung cancer refractory to platinum drugs

Н-СТ17/12,
D419МС00004

Astrazeneka Ukraine LLC

Sweden

54

International, multicenter, randomized, open-label, comparative phase 3 study to determine the efficacy of Durvalumab or the combination of Durvalumab and Tremelimumab with platinum-containing chemotherapy for first-line treatment of patients with metastatic non-small cell lung cancer

Н-СТ17/13,
D419МС00004

Astrazeneka Ukraine LLC

Sweden

55

Randomized double-blind phase II study to find the optimal dose to evaluate the safety and efficacy of Veliparib and radiotherapy throughout the brain in patients with non-small cell lung cancer metastasis to the brain

М10-897

EbbVie Biopharmaceuticals GmbH

Switzerland

56

A randomized, double-blind, multicenter phase 3 study comparing Veliparib plus carboplatin and paclitaxel in squamous cell non-small cell lung cancer

М11-089

EbbVie Biopharmaceuticals GmbH

United Kingdom

57

Prospective, multicenter, randomized, open-label, active-controlled, in two parallel groups, phase 3 studies, to compare the efficacy and safety of masitinib at a dose of 7.5 mg / kg / day with dacarbazine in patients treated with dacarbazine

23/АВ/16

Synergy Group Ukraine LLC

France

58

A prospective, multicenter, double-blind, randomized, placebo-controlled phase 3 study to evaluate the efficacy and safety of masitinib in combination with irinotecan in patients with late-stage esophageal and gastric adenocarcinoma

28/АВ/16

Synergy Group Ukraine LLC

France

59

A prospective, multicenter, open-label, centralized, group-controlled, actively controlled phase 2/3 study to evaluate gemcitabine combination versus gemcitabine monotherapy in patients with advanced / metastatic

94/АВ/16

Synergy Group Ukraine LLC

France

60

A prospective, multicenter, randomized, double-blind, placebo-controlled, phase 3 study in 2 parallel groups to compare the efficacy and safety of masitinib with docetaxel in first-line metastatic castratresis

114/АВ/16
(протокол № АВ12003)

Synergy Group Ukraine LLC

France

61

Randomized double-blind double-masked phase 3 study to compare the efficacy and safety of lefamulin (BC-3781) compared with moxifloxacin

607581001-5208і/2015

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

62

Study of the clinical effects of Fluticasone Furoate / Vilanterol (powder for inhalation at a dose of 100/25 mcg) compared with placebo on the survival of patients with chronic obstructive pulmonary disease

094806/I

Paraxel Ukraine LLC

United Kingdom

63

Study of the safety and efficacy of the combined inhaled drug fluticasone propionate / salmeterol in comparison with the inhaled drug fluticasone propionate in the treatment of adolescents and adult patients with bronchial asthma

203061/098736/І

Paraxel Ukraine LLC

United Kingdom

64

Randomized double-blind with double simulation in parallel study groups of flucticazone propionate / formoterol fumarate (Flutiform 250) 250/10 μg (2 inhalations 2 times a day) and Flutiform Ò 125/5 μn (2 inhalations 2 times a day)

FLT3509 №4019/inst

Paraxel Ukraine LLC

United Kingdom

65

A multicenter, randomized, double-blind, double-blind, parallel-group clinical trial evaluating the efficacy and safety of 24-week fixed-dose combination therapy with aclidinium bromide 400 μg

227413/7703/НЕІ

Paraxel Ukraine LLC

Sweden

66

Evaluation of the reduction of the risk of venous thromboembolism when prescribing rivaroxaban or placebo to patients with somatic pathology after inpatient treatment (MARINER)

UA00504/H_Edl

Paraxel Ukraine LLC

Belgium

67

A 52-week, double, blind, randomized, placebo-controlled study in parallel groups to evaluate the effect of 500 μg roflumilast on exacerbation rates in patients with chronic obstructive pulmonary disease treated with

358511001-695u/2012

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

68

A double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and evaluate the safety and immunogenicity of HLX02, a biosimilar of trastuzumab, and EU-derived Herceptin, a wound-derived drug.

HLX02-BC01_312_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

China

69

A multicenter, international, randomized, parallel, double-blind, placebo-controlled study of cardiovascular safety and renal microvascular effects of linagliptin 5 mg daily in diabetic patients.

1218/22_Sumy_inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

70

A 26-week, randomized, active-controlled, double-blind safety study of formoterol fumarate in free combination with inhaled corticosteroid versus inhaled corticosteroid in adolescents and adult patients with persistent asthma.

CFOR258D2416

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

71

A multicenter, randomized, double-blind, placebo-controlled oral phase study of RPC1063 as induction or maintenance therapy in patients with therapy in patients with moderate or severe ulcerative colitis.

RPC01-3101_966_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Switzerland

72

A 52-week, multicenter, double-blind, randomized, placebo-controlled study in parallel groups, a 3-phase study evaluating the efficacy and safety of traloquinumab in adults and adolescents with bronchial asthma without achieving adequate

Н-cт15/96
код D2210C00008

Astrazeneka Ukraine LLC

Sweden

73

52-week, randomized, double-blind, international, multicenter, with active control study in 2 parallel groups, comparing CHF 5993 100/6 / 12.5 μg in a metered dose inhaler, pMDI (fixed combination of extra-finely divided

ССD-05993АВ1-03 (35188)

Chiltern International Ukraine LLC

Italy

74

52-week, randomized, double-blind, international, multicenter, active control study in 2 parallel groups, comparing CHF 5993 200/6 / 12.5 μg in a metered dose inhaler, pMDI (fixed combination of extra-finely divided

ССD-05993АВ2-02 (35187)

Chiltern International Ukraine LLC

Italy

75

A 24-week, multicenter, randomized, double-blind, double-masked, placebo-controlled, and active-controlled study in parallel dose groups to evaluate the efficacy and safety of 4 doses of CHF 6001 as a dry powder for inhalation in patients with chronic obstructive pulmonary disease. lungs (hozl) on the background of basic therapy

б/н, ССD-06001АА1-01 (36590)

Chiltern International Ukraine LLC

Italy

76

Study of the effect of the drug Exenatide on reducing the frequency of cardiovascular events (EXSCEL). A randomized placebo-controlled clinical trial to evaluate the cardiovascular effects of Exenatide once weekly in patients with

108440/4517/Н/SDU

Paraxel Ukraine LLC

USA

77

Randomized double-blind with double simulation in parallel study groups of flucticazone propionate / formoterol fumarate (Flutiform 250) 250/10 μg (2 inhalations 2 times a day) and Flutiform Ò 125/5 μn (2 inhalations 2 times a day)

FLT3509 №4009/ЕІН

Paraxel Ukraine LLC (Mundipharma Research Limited)

United Kingdom

78

A randomized, double-blind, multicenter, clinical trial to evaluate the efficacy, safety, tolerability, pharmacogenetics, and immunogenicity of SB5 compared to Humira in patients with rheumatoid arthritis from

214755 SB5-G31-RA

Parexel Ukraine LLC

Korea

79

A randomized, double-blind, placebo-controlled study conducted in parallel study groups to evaluate the cardiovascular effects of Ertugliflozin treatment in patients with type 2 diabetes mellitus and established vascular disease.

МК-8835-004/В1521021, 210224/1602/і

Parexel Ukraine LLC

USA

80

Phase 3, randomized double-blind study evaluating the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

212396 В5371002 UKR/1165

Parexel Ukraine LLC

USA

81

Multicenter randomized double-blind study in parallel groups of CNTO 136 (sirukumab) when administered subcutaneously as monotherapy compared with adalimumab monotherapy in patients with active rheumatoid arthritis

214975/UA00144/Inst

Parexel Ukraine LLC

USA

82

A multicenter, randomized, double-blind, placebo-controlled study of golimumab, a monoclonal antibody to intravenous TNF-α, in patients with active psoriatic arthritis.\

UA00302/H_Edi

Parexel Ukraine LLC

Netherlands

83

Phase 3, a randomized double-blind study evaluating the efficacy and safety of PF-06410293 and adalimumab and in combination with methotrexate in patients with moderate to severe rheumatoid arthritis

212394 В5381002 UKR 2209 (20150630)

Parexel Ukraine LLC

USA

84

Phase 2b, double-blind, placebo-controlled, dose-adjusted study to evaluate the efficacy and safety of GSK3196165 in combination with methotrexate therapy in patients with moderate to high rheumatoid arthritis, not

218202/EUI(201755)

Parexel Ukraine LLC

United Kingdom

85

A randomized, double-blind, placebo-controlled, multicenter, phase 3 study conducted in parallel groups to evaluate the safety and efficacy of ustekinumab for induction and maintenance therapy in study participants with

A96UA00015/H_Edi

Parexel Ukraine LLC

Belgium

86

Evaluation of the reduction of the risk of venous thromboembolism when prescribing rivaroxaban or placebo to patients with somatic pathology after inpatient treatment

UA 00525/H_Edi

Parexel Ukraine LLC

Belgium

87

A randomized, double-blind, placebo-controlled, multicenter, phase 2b study was performed in parallel groups to evaluate the safety and efficacy of JNJ-64304500 in patients with active-phase Crohn's disease.

D52UA10001/H_Edi

Parexel Ukraine LLC

USA

88

A randomized, double-blind, placebo-controlled, multicenter, phase 3 study conducted in parallel groups to evaluate the safety and efficacy of ustekinumab for induction and maintenance therapy in study participants with

221840CS-01/16 UKR 23004 Eduk
(CSA 20170526)

Parexel Ukraine LLC

Sweden

89

A randomized, multicenter, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the effects of canagliflozin on renal endpoints in adult patients with type 2 diabetes.

28431754DIA4003/S-UA00106

Company "JANSEN PHARMACEUTICALS NV" (Belgium)

Belgium

90

52-week, double-blind, randomized, international, multicenter, active-controlled clinical trial in 2 parallel groups to study a fixed combination of beclomethasone dipropionate, formoterol fumarate and glycopyrrolate bromide administered

804645-01  (32646)

LLC "International International Ukraine

Italy

91

A 52-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase 3 study evaluating the efficacy and safety of traloquinumab in adults and adolescents with bronchial asthma without adequate control.

H-CT15/92

Astrazeneka Ukraine LLC

Sweden

92

A randomized, double-blind, parallel-group, multicenter, clinical study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of SB2 versus Remicade паціє in patients

SB2-G31-RA_Sumy_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Korea

93

A multicenter, open-label phase III study of avelaumab (MSB0010718C) compared with the use of a two-component combination based on platinum drugs as first-line therapy in PD-L1-positive, recurrent non-small cell

EMR10070-005_884_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Germany

94

A multigroup, open-label, multicenter phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and primary antitumor activity of AZD9291 in combination with increasing doses of new drugs in patients with advanced non-small cell lung cancer.

Н-СТ17/37, D5160С00006

Astrazeneka Ukraine LLC

Sweden

95

An open-label, randomized, comparative, multicenter, phase 3 clinical trial evaluating the efficacy and safety of Savolitinib versus Sunitinib in patients with MET-positive, inoperable, and locally advanced, or metastatic papillary kidney

Н-СТ17/21, D5082C00003

Astrazeneka Ukraine LLC

Sweden

96

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of AZD9291 compared with placebo in patients with stage III-IIIA non-small cell lung cancer and epidermal receptor mutation.

Н-СТ17/25, D5164С00001

Astrazeneka Ukraine LLC

Sweden

97

Phase 2 study to study the efficacy, safety and tolerability of six weeks of V565 treatment in patients with Crohn's disease

V56502_1002_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

United Kingdom

98

Randomized, controlled, double-blind, 52-week phase III study in 3 parallel groups to compare the efficacy, safety, and tolerability of the fixed dose of the triple combination FF / Umeс // VI compared to the fixed doses of the double combination FF /

4803

GlaxoSmithKline-Pharmaceuticals Ukraine LLC

United Kingdom

99

A randomized, controlled, double-blind, phase 3 study conducted in parallel groups to compare the pharmacokinetics, efficacy, and safety of ST-P10, Rituxan, and MabThera in patients with rheumatoid arthritis.

486241001-3411i/2014

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

100

A randomized, double-blind, comparative study to evaluate the pharmacokinetics, pharmacodynamics, efficacy and safety of RGB-03 and MabThera in combination with Methotrexate in patients with rheumatoid arthritis

552951005-2614i/2015

InnoPharm-Ukraine Contract Research Organization LLC

USA

101

52-week double-blind, placebo-controlled, parallel-dose study of the efficacy and safety of reslizumab subcutaneous administration at a fixed dose of 110 mg in patients with uncontrolled asthma and elevated blood eosinophils

569701007-58234і/2015

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

102

Randomized double-blind double-masked phase 3 study to compare the efficacy and safety of lefamulin (BC-3781) compared with moxifloxacin

607581001-5208і/2015

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

103

Phase 3 randomized, double-blind, active-controlled study in parallel groups to compare the efficacy and safety of CT-P10 and Rituxan in patients with low-tumor follicular lymphoma

559311601-3463і/2016

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

104

Phase 3, 24-week double-blind, placebo-controlled, concomitant studies, efficacy and safety studies of fixed dose respizumab subcutaneously (110 mg every 4 weeks) in patients with oral corticosteroid-dependent asthma

569701002-58243і/2015

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

105

A multicenter, randomized, double-blind, placebo-controlled study conducted in parallel groups to evaluate the efficacy and safety of JTE-051 in patients with active rheumatoid arthritis for 12 weeks (MOVE-RA).

587691001-2406-i/2016

InnoPharm-Ukraine Contract Research Organization LLC

USA

106

Randomized double-blind, double-blind, placebo-controlled study in parallel groups to evaluate the efficacy and safety of two doses of nebulized budesonide administered by inhalation system, with open comparison of nebulized

VR475/3/001_1911_INST

LLC "INS Research - Ukraine"

United Kingdom

107

Study of the safety and efficacy of the combined inhaled drug fluticasone propionate / salmeterol in comparison with the inhaled drug fluticasone propionate in the treatment of adolescents and adult patients with bronchial asthma

203061/098623/Іnst

Paraxel Ukraine LLC

USA

108

Study of safety and benefits of 6-month use of the combined inhaled drug fluticasone propionate / salmeterol in comparison with the inhaled drug fluticasone propionate in the treatment of 6200 children from 4 to 11 years

203060/098547/HEI

Paraxel Ukraine LLC

USA

109

A randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of a human monochannel antibody, REGN2222, for the prevention of infection caused by respiratory synthetic virus,

584671001-804894і/2016

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

110

Open-label study to evaluate the safety, tolerability and pharmacogenetics of etravirine (ETR) in combination with other antiretroviral agents (ARVs) in HIV-1 infected patients receiving antiretroviral therapy

ТМС1251 FD3002_Sumy_Hosp

Enterprise with 100% foreign investment "Quintiles Ukraine"

USA

111

Phase 3 study services to evaluate the efficacy and safety of favipiravir in adult patients with uncomplicated influenza

35291001-6243і/2013

InnoPharm-Ukraine Contract Research Organization LLC

USA

112

A randomized, double-blind, placebo-controlled phase 3 study evaluating the safety and efficacy of S-888711 (lusutrombopag) in the treatment of thrombocytopenia in patients with chronic liver disease undergoing

ТМС1251 FD3002_Sumy_Hosp

Enterprise with 100% foreign investment "Quintiles Ukraine"

USA

113

A double-blind, placebo-controlled, phase 2a study to evaluate the safety and tolerability of single intravenous VIS410 in patients with uncomplicated influenza A

VIS410-202/601hu

MB Quest LLC

USA

114

A randomized, open-label, multicenter phase III study of Durvalumab and Tremelimumab as first-line treatment for patients with unresectable hepatocellular carcinoma

Н-СТ17/40, D419СС00002

Astrazeneka Ukraine LLC

Sweden

115

Phase 2/3, multicenter, randomized, double-blind study to assess the duration of severe neutropenia with Plinabulin compared with Pegfilgrastim in patients with solid tumors receiving myelosuppressive chemotherapy

BPI-2358-105    (37099)

Chiltern International Ukraine LLC

Italy

116

Multicenter, randomized, double-blind, double-simulated, double-cross, 12-week study to evaluate the efficacy, safety, and tolerability of FPS 250/50 mcg in a ROTACHALER device and FPS 250/50 mcg in a Discus device twice daily

355181003-204201і/2013

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

117

Open, multicenter, extended phase 3 study of oral RPC1063 as therapy in patients with moderate or severe ulcerative colitis

RPC01-3102_966_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

USA

118

A randomized, double-blind, placebo-controlled study to evaluate the effect of bempedoic acid (ETS-1002) on the occurrence of severe cardiovascular events in patients with cardiovascular disease or at high risk of its occurrence who do not tolerate treatment

1002-043_26019_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

USA

119

The use of pemafibrate to reduce cardiovascular complications by lowering triglycerides in patients with diabetes

К-877-302_7331_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

USA

120

A 24-week, double-blind, randomized, placebo-controlled phase II a study conducted in parallel groups to test the concept for evaluating the efficacy and safety of two doses of 5-aminolevulinic acid when co-administered.

NPJ005-DM2-0522_Sumy_22521_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Japan

121

A randomized, double-blind, placebo-controlled, multicenter phase 2 study conducted in parallel groups to evaluate the safety and efficacy of multiple AZD 7594 dry powder inhaler dose levels.

238537 D 3741 С 00007 UKR 7707 Educ_Inst

Parexel Ukraine LLC

Sweden

122

A multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of guselcumab for subcutaneous administration in the treatment of patients with active psoriatic arthritis

СНТО1959PSA3001/F38-UA10015

Company "JANSEN PHARMACEUTICALS NV" (Belgium)

Belgium

123

A multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of subcutaneous guselcumab in the treatment of patients with active psoriatic arthritis

СНТО1959PSA3002/F26-UA10015

Company "JANSEN PHARMACEUTICALS NV" (Belgium)

Belgium

124

A multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of subcutaneous guselcumab in patients with active psoriatic arthritis and insufficient response to treatment.

СНТО1959PSA3003/М51-UA10004

Company "JANSEN PHARMACEUTICALS NV" (Belgium)

Belgium

125

Phase 2 study to study the efficacy, safety and tolerability of six weeks of V565 treatment in patients with Crohn's disease

V56502_1002_INST

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

United Kingdom

126

Open Extended Study and Safety Monitoring in Patients with Moderate or Severe Ulcerative Colitis Previously Participating in Phase III Studies of Etrolizumab

GA28951_Murenets_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Switzerland

127

A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy (maintenance of remission) and safety of etrolizumab compared with placebo in patients with moderate to severe ulcerative colitis.

GA29102_Murenets_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Switzerland

128

Multicenter, randomized, placebo-controlled phase 2 study conducted in parallel groups of the drug LY3074828

I6T-MC-AMAG_40630_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

USA

129

A randomized, double-blind, placebo-controlled phase 3 multicenter study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared to adalizumab and placebo

GA28949_317053_Inst

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

Switzerland

130

Open continuation of the study of Reslizumab at a fixed dose of 110 mg subcutaneously in patients 12 years of age and older with severe eosinophilic asthma

569701010-58297i/2017

InnoPharm-Ukraine Contract Research Organization LLC

USA

131

Randomized double-blind active-controlled phase 3 study to compare the efficacy and safety of CT-P17 and Humira in combination with methotrexate in patients with active rheumatoid arthritis

744861015-3409-і/2018

InnoPharm-Ukraine Contract Research Organization LLC

United Kingdom

132

Multicenter, randomized, double-blind, parallel-group clinical trial S-649266 compared with meropenene in the treatment of nosocomial bacterial pneumonia, ventilator-associated bacterial pneumonia, or nosocomial bacterial pneumonia

1615R2132_INST

LLC "INC Research Ukraine"

United Kingdom

133

A 12-week randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis

RLM-MD-01_Fadeieva_sCTA_INST

Allegran Limited LLC "INC Research Ukraine"

United Kingdom

134

A 46-week double-blind placebo-controlled phase 3 study with a 6-week randomized withdrawal period of the study drug to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis

RLM-MD-03_Fadeieva_sCTA_INST

Allegran Limited LLC "INC Research Ukraine"

United Kingdom

135

A 52-week randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis

RLM-MD-04_Fadeieva_sCTA_INST

Allegran Limited LLC "INC Research Ukraine"

United Kingdom

136

A multicenter, randomized, double-blind, placebo-controlled phase study of oral RPC1063 as induction or maintenance therapy in patients with moderate or severe ulcerative colitis of phase three according to the protocol

11/75-R18

PISI Ukraine LLC

Switzerland

137

Open multicenter extended phase three study to study the oral use of RPC1063 as therapy in patients with moderate or severe ulcerative colitis

30/303-R18

PISI Ukraine LLC

Switzerland

138

A prospective, double-blind, randomized, placebo-controlled phase III study to evaluate the efficacy and safety of Octagam 10% in patients with dermatomyositis

GAM10-08_95_INST-UNIV

LLC "Premier Research"

Austria

139

A randomized, double-blind, placebo-controlled phase 2b study to evaluate the safety and efficacy of MEDI8897, a monoclonal antibody to respiratory syncytial virus with a prolonged half-life, in healthy preterm infants

D5290C00003_2003316_Inst

Enterprise with 100% foreign investment "Quintiles Ukraine"

USA

140

A randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of Pimodivir in combination with standard therapy in patients with influenza A infection

63623872FLZ3001_UA10004_HOSP

Enterprise with 100% foreign investment "IKYUVIA RDS Ukraine"

USA

141

A double-blind, randomized, multicenter, controlled phase 2b study to evaluate the efficacy and safety of intravenous VIS410 in addition to oseltamiir (tamiflu) compared with oseltamivir monotherapy in hospitalized adults.

1020-0601-НА

MB Quest LLC

USA

142

A randomized, double-blind, placebo-controlled, phase III multicenter study to evaluate the efficacy and safety of Baloxavir Marboxil in combination with standard neuramidase inhibitor therapy in hospitalized patients with severe

760991001-317387і/2018

InnoPharm-Ukraine Contract Research Organization LLC

Switzerland

143

Research

WO39210-294290.I-1

ROSH Ukraine LLC

USA

144

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

065 04-03-2020 ММІ

Matej Bel

145

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

066 04-03-2020 ММІ

Dorian-Laurentiu Florea

Mexico

146

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

067 04-03-2020 ММІ

Peter Gallo

Slovakia

147

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

069 04-03-2020 ММІ

Mariana Sedliacikova

Slovakia

148

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

075 07-03-2020 ММІ

Muhammad Sajjad

Pakistan

149

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

076 11-03-2020 ММІ

Waqas Sadid

Pakistan

150

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

078 12-03-2020 ММІ

Gayane Tovmasyan

Armenia

151

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

079 25-03-2020 ММІ

Anis Urrehman Abdurehman Siddigi

Saudi Arabia

152

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

080 30-03-2020 ММІ

Metin SAYGILI

Pakistan

153

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

082 06-04-2020 ММІ

Prause Gunnar

Estonia

154

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

085 03-06-2020 ММІ

Higher School of Engineering and Economics

Czech Republic

155

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

087 03-06-2020 ММІ

Elena Sira

Belgium

156

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

083 26-05-2020 Ммі

Greta Keliotute Staniuleniene

Lithuania

157

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

084 26-05-2020 ММІ

Iveta Ubreziova

Slovakia

158

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

088 03-06-2020 Ммі

Akademia WSB

Poland

159

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

089 03-06-2020 ММІ

Fakulta Management UK V Bratislava

Slovakia

160

Scientific review and editing services for articles in the journal "Marketing and Management of Innovations"

091 30-06-2020 ММІ

Ibrahiem Mahmoud Mohamed EL Emary Attia

Saudi Arabia

161

Scientific editing of an article in the magazine "BEL"

01-06-2020 BEL

Adeshina Vahid Sadik

Canada

162

Scientific editing of an article in the magazine "BEL"

01-06-20_BEL/1

FO Wahid Damilola Olanipekun

Nigeria

163

Scientific editing of an article in the magazine "BEL"

01-06-20_BEL/3

FD Julia D. Concelman

Camano Island

164

Scientific editing of an article in the magazine "BEL"

01-06-20_BEL/4

FD Julia D. Concelman

USA

165

Scientific editing of an article in the magazine "BEL"

01-06-20_BEL/5

FD Bahaudin G. Mujtaba

USA

166

Scientific editing of an article in the magazine "BEL"

01-06-20_BEL/6

FO David Schmidz

USA

167

Scientific editing of an article in the journal "FMIR SEC"

20-05-20 FMIR SEC

Ruvan Abeisekera

Sri Lanka

168

Scientific editing of an article in the journal "FMIR

01-06-20 FMIR

FO Wahid Damiola Olanipekun

Nigeria

169

Scientific editing of an article in the journal "FMIR

01-06-20 FMIR/1

FD Hassan Eddasi

Morocco

170

Scientific editing in the journal "SEC"

01-06-20 FMIR/2

FO Onat Kibaroglu

Singapore

171

Scientific editing in the journal "SEC"

01-06-20 SEC

FO Wahid Damiola Olanipekun

Nigeria

172

Scientific editing in the journal "SEC"

03-06-20 SEC

FD Hassan Eddasi

Morocco

173

Scientific editing in the journal "SEC"

02-06-20 SEC

FO Horvat Adam

Hungary

174

Scientific editing in the journal "SEC"

06-06-20 SEC

Antonio Manuel Vargas Alcaide Calle Alemannia

Spain

175

Scientific editing in the journal "FMIR"

15-06-20 FMIR

FD Adil El Amri

176

Scientific editing in the journal "SEC"

01-07-20 SEC/1

FD Bahaudin G. Mujtaba

USA

177

Scientific editing in the journal "SEC"

02-07-20 SEC

FD Khalil D. Kaya

USA

178

Scientific editing in the journal "SEC"

03-07-20 SEC

FD Gingerbread Dutta

Bangladesh

179

Scientific editing in the journal "SEC"

04-07-20 SEC

FO Wahid Damiola Olanipekun

Nigeria

180

Scientific editing in the journal "FMIR"

31-07-20 FMIR

FO Adecunle Oludeo

Nigeria

181

Scientific editing in the journal "FMIR"

32-07-20 FMIR

FD Khalil Dinser Kaya

USA

182

Documentation and software development work

USE-16.2-67-D/K-19

State company "UKRSPETSEKSPORT"

Ukraine China

183

Supply of engineering services for technical and economic inspection and development of technical and technological documentation for the creation of chemical production LLC "D M Servis

80.11-2020./01

LLC "D M Servis"

Azerbaijan